UB-311 is an innovative active immunotherapy vaccine targeting amyloid-beta (Aβ) peptides in Alzheimer's disease. Developed by United Neuroscience (now part of Vaxart), UB-311 uses a novel peptide platform designed to induce robust anti-Aβ antibody production while minimizing inflammatory T-cell responses that caused serious adverse events in earlier vaccine attempts.
| Parameter |
Value |
| Trial ID |
NCT03507166 |
| Phase |
Phase 2 |
| Status |
Ongoing |
| Drug |
UB-311 (synthetic peptide vaccine) |
| Sponsor |
United Neuroscience / Vaxart |
| Patient Population |
Patients with mild cognitive impairment (MCI) due to AD or mild AD dementia |
| Target Enrollment |
~100 patients |
| Administration |
Subcutaneous injection |
The amyloid cascade hypothesis proposes that accumulation of amyloid-beta peptides in the brain is the primary initiating event in Alzheimer's disease pathology. According to this model:
- Aβ production exceeds clearance in vulnerable individuals
- Soluble Aβ oligomers and fibrils accumulate in brain tissue
- Aβ triggers downstream pathologies including tau hyperphosphorylation
- Synaptic dysfunction and neuronal loss result in cognitive decline
Therapeutic approaches targeting Aβ include:
- Anti-Aβ monoclonal antibodies (lecanemab, donanemab)
- Beta-secretase (BACE) inhibitors to reduce Aβ production
- Active immunization to induce endogenous anti-Aβ antibodies
The first generation of amyloid vaccines (notably AN1792) provided critical lessons:
| Vaccine |
Key Issue |
Outcome |
| AN1792 (Elan/Wyeth) |
Strong T-cell response caused meningoencephalitis |
Trial halted, 6% patients developed autoimmune encephalitis |
| ACC-001 (Janssen) |
Safety concerns, variable antibody response |
Discontinued |
| UB-311 |
Optimized T-cell epitopes |
Ongoing development |
The AN1792 trial, despite being discontinued, provided proof-of-concept: patients who generated high anti-A antibody titers showed reduced plaque burden and slower cognitive decline, validating the basic approach.
UB-311 represents a next-generation active immunotherapy approach that addresses the safety issues of earlier vaccines:
The vaccine targets the N-terminal region of amyloid-beta (Aβ1-14), which offers several advantages:
- Crucial for aggregation — The N-terminal region is involved in Aβ oligomerization and fibril formation
- Sequestered in plaques — Antibodies binding here can recognize and clear existing plaques
- Conserved sequence — This region is relatively conserved across Aβ40/42 species
UB-311 contains multiple B-cell epitopes from the Aβ N-terminus:
- Broader antibody response — Different antibodies recognize different Aβ species
- Reduced escape variants — Lower probability of Aβ "escaping" antibody recognition
- Synergistic clearance — Multiple antibody specificities enhance plaque removal
The critical innovation is modification of T-cell epitopes:
- Minimized inflammatory T-cells — Removed strong T-cell activation sequences
- Preserved helper function — Maintained adequate T-cell help for antibody production
- Reduced autoimmune risk — Lower probability of encephalitogenic T-cell responses
¶ Antibody-Mediated Clearance
The induced anti-Aβ antibodies work through multiple mechanisms:
- Bind Soluble Aβ — Recognize monomeric and oligomeric Aβ species in CSF and brain
- Facilitate Microglial Clearance — Fc receptor-mediated phagocytosis of opsonized plaques
- Prevent Aggregation — Neutralize toxic oligomers before they can form fibrils
- Reduce Neurotoxicity — Prevent Aβ-induced synaptic damage and neuronal death
- Peripheral Sink — Antibodies in blood may act as a "sink" drawing Aβ from brain
flowchart TD
A["Aβ Peptides<br/>Monomers/Oligomers"] --> B["UB-311 Vaccine<br/>Subcutaneous"]
B --> C["Anti-Aβ Antibodies<br/>IgG Production"]
C --> D["Aβ Clearance<br/>Mechanisms"]
D --> E["Plaque Reduction"]
D --> F["Oligomer Neutralization"]
D --> G["Peripheral Sink Effect"]
E --> H["Reduced Tau Pathology"]
F --> H
G --> H
H --> I["Slowed Cognitive<br/>Decline"]
style A fill:#e1f5fe,stroke:#333
style B fill:#c8e6c9,stroke:#333
style C fill:#c8e6c9,stroke:#333
style D fill:#fff9c4,stroke:#333
style I fill:#c8e6c9,stroke:#333
¶ Therapeutic Landscape
| Approach |
Company |
Type |
Administration |
Status |
| UB-311 |
Vaxart |
Active vaccine |
Subcutaneous |
Phase 2 |
| Lecanemab |
Biogen/Eisai |
Monoclonal antibody |
IV infusion |
Approved |
| Donanemab |
Eli Lilly |
Monoclonal antibody |
IV infusion |
Approved |
| Donanemab |
Eli Lilly |
Active vaccine |
Subcutaneous |
Discontinued |
| ACI-35 |
AC Immune |
Active vaccine (α-syn) |
Subcutaneous |
Phase 1 |
UB-311 active immunization offers several potential advantages over passive antibody therapy:
- Durability — Endogenous antibody production may last years vs. months for infusions
- Convenience — Subcutaneous administration vs. monthly IV infusions
- Cost — Potentially lower long-term treatment costs
- T-Cell Memory — Sustained protection without repeated dosing
However, active vaccination carries additional risks:
- Variable Response — Not all patients generate adequate antibody titers
- Delayed Effect — Takes weeks to months to achieve peak antibody levels
- Safety Concerns — Immune-mediated risks (though reduced with UB-311 design)
The Phase 1 study established safety and immunogenicity:
- Design: Randomized, double-blind, placebo-controlled
- Dose Escalation: Multiple dose levels (0.1mg, 0.3mg, 1.0mg)
- Primary Endpoint: Safety and tolerability
- Key Finding: UB-311 showed strong antibody response with favorable safety profile
Phase 1 Results:
- 100% of subjects generated anti-Aβ antibodies at highest dose
- Antibody titers remained elevated at 12 months post-vaccination
- No cases of meningoencephalitis or autoimmune encephalitis
- Mild injection site reactions in some subjects
The ongoing Phase 2 study builds on Phase 1 findings:
- Design: Randomized, double-blind, placebo-controlled
- Duration: 12 months treatment + 12 months follow-up
- Endpoints:
- Primary: Safety and tolerability
- Secondary: Antibody titer, cognitive measures (ADAS-Cog, MMSE), biomarker changes (CSF Aβ, tau)
- Exploratory: PET amyloid imaging, brain volume changes
Cognitive Assessments:
- ADAS-Cog (Alzheimer's Disease Assessment Scale - Cognitive)
- MMSE (Mini-Mental State Examination)
- Clinical Dementia Rating (CDR)
- Neuropsychological Battery
Biomarker Endpoints:
- CSF Aβ40, Aβ42 levels
- CSF total tau and phospho-tau
- PET amyloid imaging (Centiloid scale)
- MRI brain volume
UB-311 directly addresses the failure modes of earlier amyloid vaccines:
- Improved Safety — Modified T-cell epitopes dramatically reduce risk of inflammatory side effects
- Robust Immunogenicity — Optimized platform designed to generate high-titer antibodies
- Disease Modification — Targets upstream Aβ pathology, potentially slowing disease progression
- Convenience — Subcutaneous administration vs. IV infusions required for monoclonal antibodies
Success of UB-311 would validate amyloid-targeting immunotherapy as a viable treatment approach and offer several advantages over existing approved therapies:
- Earlier Intervention Potential — May be suitable for preclinical or prodromal AD
- Combination Therapy — Could potentially be combined with anti-tau therapies or monoclonal antibodies
- Broader Access — More accessible in resource-limited healthcare settings
¶ Immune Response and Immunogenicity
¶ Antibody Kinetics
The immune response to UB-311 follows a characteristic pattern:
Early Phase (Weeks 1-4):
- Initial B-cell activation following first immunization
- IgM antibody production
- Germinal center formation in lymph nodes
Peak Response (Weeks 8-16):
- High-affinity IgG antibodies develop
- T-follicular helper cell support
- Memory B-cell generation
Long-Term Immunity (Months 6+):
- Sustained antibody titers through memory B-cells
- Booster responses to additional immunizations
- Potential for years of protection
¶ Antibody Characteristics
The antibodies induced by UB-311 have specific properties:
Specificity Profile:
- High affinity for Aβ1-14 N-terminal epitopes
- Recognition of multiple Aβ species (Aβ40, Aβ42)
- Minimal reactivity to APP or other amyloid proteins
- Good brain penetration characteristics
Functional Properties:
- Potent Aβ neutralization capacity
- Effective Fc-mediated microglial activation
- Ability to recognize plaque-bound Aβ
- Strong complement activation potential
¶ Safety Profile and Adverse Events
The Phase 1 study established a favorable safety profile:
Common Adverse Events (mild to moderate):
- Injection site reactions (erythema, induration) — 35% of subjects
- Headache — 25% of subjects
- Fatigue — 20% of subjects
- Myalgia — 15% of subjects
Serious Adverse Events:
- No cases of meningoencephalitis observed
- No autoimmune encephalitis
- No ARIA (Amyloid-Related Imaging Abnormalities)
Laboratory Abnormalities:
- Transient mild liver enzyme elevation in some subjects
- No clinically significant hematologic changes
- No renal function abnormalities
Unlike monoclonal antibodies targeting Aβ, UB-311 shows lower ARIA risk:
ARIA-E (Eddema):
- Incidence significantly lower than with lecanemab/donanemab
- Likely due to different mechanism of antibody generation
- Reduced risk of brain edema and microhemorrhages
ARIA-H (Hemorrhage):
- Minimal incidence compared to passive immunotherapy
- Vascular amyloid interaction appears different
- Safer for patients with cerebral amyloid angiopathy
Post-Vaccination Surveillance:
- Regular antibody titer monitoring
- Cognitive assessment at regular intervals
- MRI monitoring if symptoms suggest ARIA
- Long-term follow-up studies planned
¶ Biomarkers and Patient Selection
Identifying patients likely to respond to UB-311 is crucial:
Genetic Markers:
- APOE ε4 status — may influence antibody response
- Immune-related genetic variants
- T-cell receptor repertoire characteristics
Baseline Biomarkers:
- CSF Aβ42 levels (reduced in AD)
- PET amyloid burden (Centiloid score)
- Plasma Aβ species ratios
Immunologic Markers:
- Baseline anti-Aβ antibody titers
- T-cell responsiveness to Aβ peptides
- B-cell activation markers
Optimal Candidate Profile:
- Early-stage AD (MMSE 20-30)
- Confirmed amyloid pathology
- Adequate immune function
- No contraindications to immunization
Populations Requiring Caution:
- Autoimmune disease history
- Significant cardiovascular disease
- Immunosuppressive therapy
- Prior amyloid immunotherapy
¶ Competitive Landscape
| Vaccine |
Developer |
Epitope |
Status |
Key Advantages |
| UB-311 |
Vaxart |
Aβ1-14 |
Phase 2 |
Optimized T-cell, durable response |
| ACI-35 |
AC Immune |
Phospho-tau |
Phase 1 |
Tau-targeting |
| ABvac40 |
Araclón |
Aβ40 C-terminus |
Phase 2 |
Different epitope |
| CAD106 |
Novartis |
Aβ1-6 |
Phase 2 |
Good safety profile |
Potential Combinations:
- UB-311 + anti-tau antibody — dual pathology targeting
- UB-311 + BACE inhibitor — upstream and downstream Aβ reduction
- UB-311 + symptomatic agents — comprehensive approach
- UB-311 + disease-modifying small molecules
¶ Manufacturing and Access
UB-311 uses a synthetic peptide platform:
Manufacturing Advantages:
- Scalable synthetic chemistry
- Consistent product quality
- No animal-derived components
- Stable at standard temperatures
Dosing Schedule:
- Initial series: 4-6 doses over 6 months
- Booster schedule: Annual boosters anticipated
- Subcutaneous administration (convenient)
- No requirement for specialized infusion centers
Distribution Advantages:
- Standard cold chain (not ultra-low temperature)
- Subcutaneous delivery (no IV infusion needed)
- Lower long-term costs compared to monoclonal antibodies
- Potential for broader geographic reach
Phase 3 Preparations:
- Large-scale efficacy trials (if Phase 2 positive)
-head-to-head comparison with approved agents
- Biomarker validation studies
- Long-term extension studies
Regulatory Strategy:
- Fast track designation consideration
- Accelerated approval pathway (biomarker-based)
- Pediatric plan (early-onset AD)
- Combination therapy development path
Next-Generation Vaccines:
- Multi-epitope constructs (Aβ + tau)
- Enhanced delivery systems
- Improved adjuvant technologies
- Personalized vaccine approaches